🟢 Immunitybio is trading 10.3% up today amid biotech sector gains; no company catalyst confirmed

Immunitybio is trading at $8.62, up +10.31%, with biotech strength providing context; no confirmed company-specific catalyst was identified for October 27.

• The biotech sector rose 2.18% during the regular session.
• A report linked overnight attention to Jim Cramer calling ImmunityBio a “very good spec,” but this does not establish the cause of the intraday rise.
• The trial database-lock update predates the move, with results expected in November. Available evidence points more to sector strength than a confirmed ImmunityBio event.